In November 2018, a cancer vaccine being developed by Epitopoietic Research Corp. became the first drug to be given to a U.S. patient under new “right-to-try” legislation that gives terminally ill patients access to experimental drugs. The right-to-try law dictates that any compound used in this way must have successfully completed Phase 1 safety testing and be under the FDA’s ongoing approval process. (FierceBiotech)